Immune Monitoring and Biomarker Assays for Antibody & Bispecific Therapeutics
Accelevir provides bispecific antibody immune monitoring, monoclonal antibody biomarker analysis, and cytokine release syndrome (CRS) detection assays to ensure patient safety and confirm therapeutic mechanism. Our immune subset phenotyping antibody therapy workflows meet GLP standards for pivotal trials.
Challenges in Antibody & Bispecific Development
- Immune subset dynamics: Measuring target cell depletion or activation.
- Mechanism confirmation: Demonstrating intended immune modulation.
- CRS risk: Detecting early cytokine spikes.
- Combination trial complexity: Disentangling effects in multi-agent regimens.
How Accelevir Supports Antibody Programs
- Immune Subset Phenotyping
- Multiparameter flow cytometry for T, B, NK cells and myeloid populations.
- Activation/exhaustion markers to monitor therapeutic effect.
- Functional Immunoassays
- ELISpot/ICS for antigen-specific T-cell activity.
- Cytolytic assays to confirm target cell killing.
- Cytokine & Chemokine Profiling
- Multiplex Luminex and ELISA panels for CRS detection and immunomodulation tracking.
- Biomarker Correlation Studies
- Longitudinal monitoring to link immune changes with clinical outcomes.
Why Partner with Accelevir
- Deep experience in high-parameter immune monitoring.
- GLP-capable assays for pivotal trials.
- Integrated biomarker strategy from early phase to market.